

# **RADIATION FORUM**

### CHELSEA HOTEL, TORONTO, ON ROOM: ROSSETTI

### FRIDAY MAY 03, 2024 8:00 AM - 12:00 PM

CO-CHAIRS : MICHAEL MCKENZIE AND SCOTT MORGAN SENIOR INVESTIGATOR: WENDY PARULEKAR

#### CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

#### Learning Objectives:

- To integrate current knowledge regarding molecular biology and new therapeutics in clinical trials evaluating radiotherapy.
- To review relevant data from clinical studies evaluating radiotherapy interventions conducted by the Canadian Cancer Trials Group or its collaborators.
- To integrate optimal statistical methodologies in clinical trial design.
- To provide a learning environment supportive to investigators.

#### 8:00 am Welcome and Introductions

M. McKenzie & S. Morgan

S. Morgan

#### 8:05 am <u>CCTG Led and Intergroup Ongoing Trials Previously Presented</u>

Intergroup Trials:

S1827: MRI Brain Surveillance Alone versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK). **BRC.8** 

ANZUP 1801: DASL-HiCaP: Darolutamide Augments Standard Therapy For Localized Very High-Risk Cancer Of The Prostate. A Randomized Phase 3 Double-Blind, Placebo-Controlled Trial Of Adding Darolutamide To Androgen Deprivation Therapy And Definitive Or Salvage Radiation In Very High Risk, Clinically Localized Prostate Cancer. **PR.22** 

NRG BR007: A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage 1, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </=18 Breast Cancer (DEBRA). **MAC.28** 

#### CCTG Led Trials:

Tailor RT: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive And T3N0 Breast Cancer. **MA.39** 



CCTG is a CCS national program.

	A Phase III Trial of Stereotactic Radiosurgery Compared with Hippocampal- Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases. <b>CE.7</b>	
	A Randomized Phase II Trial Evaluating High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer. <b>PR.19</b>	
	PLATON: A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer. <b>PR.20</b>	
	Randomized Phase II Study of Cisplatin + RT vs Durvalumab + RT followed by Adjuvant Durvalumab vs Durvalumab + RT followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Ca (LA-OSCC). <b>HN.9</b>	
	A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma. <b>HN.10</b>	
8:30 am	Recently Activated CCTG Studies	
	RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials - The MMRD-GREEN trial <b>EN.11</b>	S. Welch
	SPECT-CT Guided ELEctive Contralateral Neck Treatment (SELECT) for Patients with Lateralized Oropharyngeal Cancer. A Phase III Randomized Controlled Trial. <b>HN.11</b>	A. Hosni
	Androgen Suppression Combined with Elective Nodal Irradiation and Dose Escalated Prostate Treatment: A Non-Inferiority, Phase III Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost (ASCENDE-SBRT). <b>PR.24</b>	A. Loblaw
	A Phase II Study of Tailored Adjuvant Therapy in POLE-mutated and p53- wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER). EN.10	K. Han
9:10 am	CCTG Approved Studies Pending Activation	
	Optimizing Head and Neck Tumour And Symptom Control in Patients Unable to Tolerate Curative Intent RT: A Phase III Trial Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study). <b>HN.13</b>	l. Poon
	A Randomized Phase 3 Trial Comparing Stereotactic Body Radiotherapy to Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases. SC.29	W. Parulekar

### 9:30 am BREAK



# 9:45 am <u>New Study Proposals</u>

Hypofractionated radiotherapy for hematological malignancies (ZOOM)	N. Ahmed
Stereotactic Ablative Radiation Therapy for Oligoprogressive Endometrial Cancer on Systemic Therapy (PRIMER)	E. Leung
A Randomized Phase II/III trial of Immunotherapy with Delayed and Reduced Volume Elective Radiotherapy (REVERT) in patients with High Risk HNSCC	A. McPartlin

# 12:00pm Meeting Adjourned



CCTG is a CCS national program.